In recent years, targeting c-Met/HGF has emerged as a relevant strategy in cancer treatment, and several compounds with this mechanism of action have reached the market. Researchers from the First Affiliated Hospital of Wenzhou Medical College and colleagues reported on the design and characterization of a novel series of 4-(4-amino phenoxy) picolinamide derivatives that led to the identification of [I] as the lead compound.